Local 12: Chemotherapy in recurrent ovarian cancer patients
UC researcher publishes New England Journal of Medicine study looking at outcomes
The five-year survival rate for ovarian cancer is only 36%, one of the worst cancer survival rates out there.
Finding the right treatments, however, is critical to changing that survival rate, according to Dr. Thomas Herzog, a professor at UC and gynecologic oncologist with UC Health. His team just released a study in the New England Journal of Medicine comparing those who just had chemotherapy with a recurrent cancer and those who had chemotherapy in addition to surgery when the cancer came back.
Featured photo courtesy of Unsplash.
Related Stories
The future, decoded. UC scholars reveal what’s next
May 20, 2026
The University of Cincinnati’s NEXT Innovation Scholars presented Gen Z-fueled insights on possible future trends at the Futures Forum 2026. Here’s what they see ahead.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.
UC researchers recruit older adults for extreme heat health study
May 20, 2026
The University of Cincinnati’s Center for Collaboration on Climate & Community for Health (C4H) is recruiting older adults to participate in a study tracking their health during periods of extreme summer heat.